Status:
UNKNOWN
A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.
Lead Sponsor:
China Medical University Hospital
Conditions:
"Hyperuricemia,Anserine"
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Hyperuricemia is a common metabolic disorder.The Yaizu Suisankagaku Industry Company have developed industrial production named Marine Active, was able to offer anti-fatigue activity by animal trial d...
Detailed Description
Hyperuricemia is a common metabolic disorder. It can result from a decreased renal uric acid excretion, increased urate production, or both. The classical association with clinical gout is well-known....
Eligibility Criteria
Inclusion
- Male or female patients, age between 18 to 60 years
- With the data of serum uric acid level more than 8.0 mg/dl within 2 weeks before the initiation of study
- Signed informed consent obtained prior to inclusion into the study
Exclusion
- Pregnant women.
- Acute onset of gouty arthritis or renal stone
- Significant liver or renal dysfunction, hematological disease, oncological disease, or other life threatens disorders.
- Condition that need the management of diuretics or analgesics agent
- Have been administrated by anti-hyperuricemia agent or healthy food with in 4 weeks before the initiation of study.
- The serum uric acid level could be decrease to lower than 8 mg/dl by diet control.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00208000
Start Date
July 1 2004
End Date
April 1 2006
Last Update
November 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospita
Taichung, Taiwan, 404